OCGN insider transaction filings
Ocugen, Inc. — 33 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-11. Screen OCGN transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 1 filing by 1 insider — 525,991 shares, $589,110 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 468,727 shares @ $1.12 ($524,974) by Musunuri Shankar, filed 2026-09-11.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Musunuri Shankar — Chief Executive Officer, Director | 1 | — | 2 legs · 525,991 sh · $589,110 | — |
Recent Form 4 filings — Ocugen, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-11 | 4 | Musunuri Shankar — Chief Executive Officer, Director | Sale (S): 468,727 @ $1.12 · Sale (S): 57,264 @ $1.12 | EDGAR |
| 2026-06-17 | 4 | Johnson-Greene Treerita Essalima — Chief Financial Officer | Purchase (P): 21,000 @ $1.23 | EDGAR |
| 2026-06-15 | 4 | Kompella Uday — Director | Grant/award (A): 170,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Chandrasekhar Satishchandran — Director | Grant/award (A): 170,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Castillo Kirsten — Director | Grant/award (A): 170,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Zhang Junge — Director | Grant/award (A): 170,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Coleman Blaise — Director | Grant/award (A): 170,100 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Zhang Junge — Director | Option exercise (M): 15,000 @ $0.51 · Option exercise (M): 112,205 @ $0.46 · Option exercise (M): 66,929 @ $1.42 · Option exercise (M): 15,000 (derivative) @ $0 · Option exercise (M): 112,205 (derivative) @ $0 · Option exercise (M): 66,929 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Musunuri Shankar — Chief Executive Officer, Director | Grant/award (A): 3,123,201 @ $0 · Grant/award (A): 3,123,201 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Ramachandran Ramesh — Chief Accounting Officer | Grant/award (A): 207,300 @ $0 · Grant/award (A): 310,950 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Chandrasekhar Satishchandran — Director | Grant/award (A): 151,316 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Coleman Blaise — Director | Grant/award (A): 151,316 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Castillo Kirsten — Director | Grant/award (A): 151,316 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Kompella Uday — Director | Grant/award (A): 151,316 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Zhang Junge — Director | Grant/award (A): 151,316 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Ramachandran Ramesh — Chief Accounting Officer | Grant/award (A): 350,146 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Upadhyay Arun — See Remarks | Tax withholding (F): 41,633 @ $0.89 · Grant/award (A): 730,994 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Musunuri Shankar — Chief Executive Officer, Director | Tax withholding (F): 177,146 @ $0.89 · Grant/award (A): 1,827,485 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Qamar Huma — Chief Medical Officer | Grant/award (A): 1,145,468 (derivative) @ $0 | EDGAR |
| 2024-12-02 | 4 | Fernandes Prabhavathi — Director | Purchase (P): 10,000 @ $0.91 | EDGAR |
| 2024-11-26 | 4 | Castillo Kirsten — Director | Purchase (P): 25,000 @ $0.91 | EDGAR |
| 2024-09-26 | 4 | Upadhyay Arun — See Remarks | Tax withholding (F): 842 @ $1.17 | EDGAR |
| 2024-07-02 | 4 | Kompella Uday — Director | Grant/award (A): 66,929 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Castillo Kirsten — Director | Grant/award (A): 66,929 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Zhang Junge — Director | Grant/award (A): 66,929 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Fernandes Prabhavathi — Director | Grant/award (A): 66,929 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | Upadhyay Arun — See Remarks | Tax withholding (F): 917 @ $1.42 | EDGAR |
| 2024-07-02 | 4 | WHITTINGTON MARNA C — Director | Grant/award (A): 66,929 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Qamar Huma — Chief Medical Officer | Grant/award (A): 308,465 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Musunuri Shankar — Chief Executive Officer, Director | Tax withholding (F): 180,204 @ $0.65 | EDGAR |
| 2024-01-05 | 4 | Upadhyay Arun — See Remarks | Tax withholding (F): 41,633 @ $0.65 | EDGAR |
| 2024-01-04 | 4 | Musunuri Shankar — Chief Executive Officer, Director | Grant/award (A): 492,126 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | Upadhyay Arun — See Remarks | Grant/award (A): 137,795 (derivative) @ $0 | EDGAR |
Recent 8-K events — Ocugen, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-06-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-14 | 8-K | 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2026-05-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=OCGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →